Clinical Programs Update News Today

GuruFocus Article or News written by GuruFocusNews and the topic is about:

Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook - read this article along with other careers information, tips and advice on BioSpace

Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook - Continue to advance and expand opportunities with established... | April 3, 2022

– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash,…

– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash,...

Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities - read this article along with other careers information, tips and advice on BioSpace

– Company advancing diversified portfolio focused on areas of significant unmet medical need – Supported by solid financial position with cash to fund…

– Company advancing diversified portfolio focused on areas of significant unmet medical need– Supported by solid financial position with cash to fund...

expected beyond 2023 CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the first quarter ended March 31, 2021. The Company also provided an update on its preclinical and clinical development programs. “Over the cour...

expected beyond 2023 CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- AEterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the first quarter ended March 31, 2021. The Company also provided an update on its preclinical and clinical development programs. “Over the course...